Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.36 USD | -2.48% | -7.09% | +6.79% |
Apr. 25 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
Apr. 25 | Sector Update: Health Care | MT |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.79% | 926M | C- | ||
+7.71% | 220B | B | ||
+6.25% | 185B | B- | ||
+10.60% | 133B | B- | ||
+26.73% | 107B | A- | ||
-0.57% | 62.91B | A- | ||
+15.42% | 53.34B | B+ | ||
-1.89% | 47.71B | B+ | ||
-1.91% | 40.29B | A | ||
+11.16% | 39.57B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAB Stock
- Ratings Standard BioTools Inc.